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ABSTRACT
Objectives Early diagnosis and timely treatment are 
key elements of a successful healthcare system. We 
assessed the role of socioeconomic and cultural norms 
in accelerating or decelerating uptake and utilisation of 
health technologies into policy and practice.
Setting Secondary and tertiary level healthcare facilities 
(HCFs) in three East African countries. Level of HCF 
was selected based on the WHO recommendation for 
implantation of tuberculosis (TB) molecular diagnostics.
Participants Using implementation of TB diagnostics as a 
model, we purposively selected participants (TB patients, 
carers, survivors, healthcare practitioners, community 
members, opinion leaders and policy- makers) based 
on their role as stakeholders. In- depth interviews, key 
informant interviews and focus group discussions were 
held to collect the data between 2016 and 2018. The 
data were transcribed, translated, coded and analysed by 
thematic- content analysis.
Results A total of 712 individuals participated in 
the study. Socioeconomic and cultural factors such 
as poverty, stigma and inadequate knowledge about 
causes of disease and available remedies, cultural 
beliefs were associated with low access and utilisation 
of diagnostic and treatment tools for TB. Poverty made 
people hesitate to seek formal healthcare resulting in 
delayed diagnosis and resorting to self- medication and 
cheap herbal alternatives. Fear of stigma made people 
hide their sickness and avoid reporting for follow- up 
treatment visits. Inadequate knowledge and beliefs were 
fertile ground for aggravated stigma and believing that 
diseases like TB are caused by spirits and thus cured by 
spiritual rituals or religious prayers. Cultural norms were 
also the basis of gender- based imbalance in accessing 
care, ‘I could not go to hospital without my husband’s 
permission’, TB survivor.
Conclusion Our findings show that socioeconomic and 
cultural factors are substantial ‘roadblocks’ to accelerating 
the uptake and utilisation of diagnostic and treatment 
tools. Resolving these barriers should be given equal 
attention as is to health system barriers.
INTRODUCTION
Tuberculosis (TB) claims more than a million 
lives every year of which the poorest of the 
world are most affected.1–4 Considerable 
technological advances have been made in 
the diagnosis and treatment of TB but they 
remain less accessible to the communities 
that need it the most.5–7 Only two thirds of 
the global reported TB cases are confirmed 
by a laboratory test2
Tanzania, Uganda and Kenya are among 
the 30 countries with highest burden of TB 
as well as TB/HIV coinfection in the world.1 
The high TB burden is characterised by poor 
diagnostic capability where many of high 
burdened countries still depend on micros-
copy, a less sensitive tool for diagnosis.8–11 
Each of the three countries has a national 
TB and Leprosy control programme through 
which TB services are provided.12 Diagnosis 
and treatment are free though the prediag-
nosis screening that most patients go through 
is not free. The length of time taken to getting 
proper diagnosis depends on the healthcare 
Strengths and limitations of this study
 ► This is a qualitative assessment using triangulated 
data sources to strengthen the validity of results.
 ► Valuable insights into the role of socioeconomic and 
cultural barriers on access and utilisation of tuber-
culosis technologies.
 ► Investigators were experienced and well trained on 
qualitative data collection.
 ► Views of 712 participants may not necessarily rep-
resent views of everyone in East Africa.
 ► Participant’s ability and/or inability to recall past 
events may limit the accuracy of the data collected.
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worker’s ability to recognise TB symptoms and person’s 
health seeking behaviour. Although medicines are free, 
patient care and transports costs to and from healthcare 
facilities (HCFs). WHO approved Molecular diagnos-
tics, Xpert Mycobacterium tuberculosis/Rifampicin (MTB/
RIF) test and Line probe assay for rapid detection of TB 
and drug resistance that have been found to be imple-
mentable though the socioeconomic changes associated 
with their uptake and utilisation are less elucidated.10 13
Knowledge of disease, social and cultural issues have 
been highlighted as important factors in the patient diag-
nosis and treatment pathway of TB.14 Studies conducted 
elsewhere regarding TB and social cultural barriers 
have revealed that there is a complex interplay between 
contextual factors and community understanding of the 
disease. Cultural beliefs about causality and treatment‐
seeking paths were often mentioned in conjunction with 
biomedical views.15 There was a strong interface between 
TB and HIV in communities, and knowledge of TB is 
often confused with HIV, additionally HIV‐related stigma 
has been extended to those living with TB.15 The stigma 
of TB infection being related to HIV infection has been 
shown to have an impact on patients seeking treatment 
and their adherence to treatment.16–18 These cultural 
barriers have been reported in most African communities 
where TB infection is associated or linked to witchcraft 
as responsible for leading to delay in accessing diagnosis 
and treatment of TB.19–21 Interestingly, lack of access to 
media was highlighted as significantly associated with low 
TB knowledge.22
Socioeconomic activities such as mining are reported 
high risk for communicable illness including TB and 
HIV/AIDS.19 Population migration has been shown to 
facilitate transmission of TB as well as causing treatment 
disruptions.23 24 We set out to investigate these factors and 
the ways they impede uptake of health technologies in 
order to inform models for resolution in the East African 
region and the low- income and medium- income coun-
tries setting at large. We show that socioeconomic and 
cultural norms substantially limit access and utilisation to 
healthcare services and resolving them is fundamental to 
having well- functioning health systems.
METHODS
Approach
This was a qualitative part of a larger mixed methods 
study assessing health system and wider community 
impediments and opportunities to unlock them in order 
to achieve effective uptake and utilisation of diagnostic 
and treatment tools. Implementation of WHO approved 
TB diagnostics was used as benchmark to evaluate the 
phenomenon. The study was conducted between January 
and December 2017 in Uganda, Kenya and Tanzania. At 
the time of the study, only Kenya was defined as a middle- 
income country, and it has now been joined by Tanzania 
in this classification. This means the Tanzania results in 
this study reflect a low- income country setting.
Study design, participants and researchers
This was a cross- sectional study targeting TB patients and 
survivors, caregivers, general members of the commu-
nity served by the HCF, healthcare practitioners, opinion 
leaders, local government authorities and policy/decision 
makers at local and national levels from these three coun-
tries. An interdisciplinary team of researchers consisting 
of social scientists, biomedical scientists and clinicians 
conducted the study.
Context
Although the study countries: Kenya, Tanzania and 
Uganda are high TB burden countries, the study did not 
aim to study TB as a disease but as a prism to look into the 
challenges to increasing access to health technologies. 
Although there are pockets of uniqueness in each country, 
there is substantial level of cross border interaction and 
similarities in political and health system administrative 
structures. The differences and similarities provided the 
ideal context to study common socioeconomic- cultural 
issues and how they impact access and use of diagnostic 
and treatment tools.
Sampling strategy
A purposeful sampling method was used to select partic-
ipants based on these categories and also to ensure 
representation by age, socioeconomic status, gender and 
geographical location. A combination of in- depth inter-
views (IDI) and focus group discussions (FGDs) were 
used to generate data for this study. Participants who 
participated in the IDIs were different from those who 
participated in the FGDs. Participants for the FGDs were 
identified through the community leads who acted as 
important gate keepers in accessing these groups of partic-
ipants, as they knew the area very well, were respected 
and trusted by the community, and were able to help 
with identifying potential participants. In each selected 
administrative region, five FGDs were undertaken with 
12 participants per group and 10 IDIs were performed. 
FGDs were meant to capture a collective opinion over 
issues concerning diagnosis and treatment of TB. IDIs 
were to get a deeper opinion of individuals without inter-
ference or fear of others (online supplemental material: 
interview guide for focus groups).
Data management and analysis
All the IDI and key informant interviews (KIs) and FGDs 
were conducted by a trained qualitative data investiga-
tors who underwent a 5- day training held in Kampala, 
Uganda, May 2016. All the data collection tools including 
questionnaires and interview guides were pretested and 
revised for clarity and accuracy prior to being used in the 
field. The interviews were conducted in Swahili in Kenya 
and Tanzania and/or English in Uganda, in the offices 
or health facilities depending on the group of respon-
dents. Audio recorders were used to record all interviews 
with permission from the respondents. Collected data 
were transcribed verbatim from Swahili and translated 
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to English before being analysed by thematic- content 
approach.25 Data were coded and synthesised using both 
inductive and deductive techniques by the first author 
and reviewed by two other qualitative data investigators 
for consistency to produce list of themes, theme models 
and classification related to the themes.26 In keeping with 
the measures advised by Barbour27 independently, two 
researchers read and reread all focus group and inter-
view data, recording the emergent themes. The process 
involved careful reading of the interview transcripts for 
pattern recognition which were later translated to cate-
gories, subcategories in order to draw the conclusions 
from the data meanwhile developing themes. Themes 
further analysed to identify subthemes. However, in the 
process where there was disagreement in the themes and 
subthemes developed, discussion took place until agree-
ment to ensure trustworthy of the data was achieved.27 28
Public involvement statement
This was a people- centred study involving people at grass-
roots up to policy- makers. The views presented in the 
paper are views of the community groups and individuals 
in the study countries. This qualitative paper is the voice 
of the people: patients, survivors, carers, opinion leaders 
and policy- makers. Regional and national public and 
policy- makers’ gatherings were held to share the find-
ings of the study and policy briefs submitted to respective 
ministries of health.
RESULTS
A total of 712 participants above 18 years of age partici-
pated in this study of whom 70% were females. Sixty- five 
per cent were from rural areas. Table 1 highlights the 
characteristics of the study participants. Eight catego-
ries of individuals participated including 38 laboratory 
technicians, 37 medical administrators, 29 political 
leaders, 42 TB patients and survivors, 36 key informants, 
42 healthcare providers, 27 caregivers and 19 private prac-
titioners in the private and public sectors. One hundred 
and eight FGDs were held among community members, 
TB patients and caregivers. A total of 270 IDI including 
KIs were conducted (table 1).
Participants came from 13 regions and fourteen coun-
ties with high prevalence of TB and HIV. In Tanzania, 
the study was conducted in the following 13 regions: 
Kilimanjaro, Manyara, Tanga, Mwanza, Kagera, Kigoma, 
Singida, Mbeya, Dodoma, Dar- es- salaam, Mtwara, Rukwa 
and Katavi. In Kenya, the study was conducted in the 
following 14 counties: Taita, Taveta, Mombasa, Garrisa, 
Wajir, Meru, Marsabit, Makueni, Muranga, Nairobi, West 
Pokot, Bomet, Bongoma and Nyamira. In Uganda, the 
study was conducted in the following regions and subre-
gions including Northern region in Karamoja, Lango, 
Acholi and West Nile; Eastern region in Teso, Sebei, 
Bugisu, Bugwere, Samia, Bunyole, Jopathola and Busoga 
subregion of Uganda; Southern region in Buganda, 
Buuruuli and Kooki subregion of Uganda; Western 
region in Bunyoro, Rwenzori, Ankole and Kigezi subre-
gion of Uganda (figure 1).
Interview and FGD outcomes
A total of 712 interviews and FGD transcripts were 
obtained. Following analysis, the responses were grouped 
into two thematic categories: sociocultural and socioeco-
nomic barriers, each containing subthemes including: 
knowledge of TB, diagnosis and treatment, size, taste and 
number of pills and side effects of TB treatment and work 
patterns and responsibilities.
Sociocultural barriers
Beliefs and use of complementary medicine
Several beliefs about TB disease, its causes and treat-
ment existed in the community that delayed community 
members to seek care at health facilities. Regarding the 
cause of TB, some participants believed that it is caused 
by witchcraft. For example, one TB patient said,
‘…Before I was diagnosed to have this disease, I had 
consulted more than one traditional healer. My moth-
er believed that I was bewitched’ (TB patient, 3 TZ).
In addition to cultural beliefs about the cause of TB, 
a variety of beliefs about alternative medicines of TB in 
the community were widespread as reported by the study 
participants. The community members did believe that 
the readily available local medicines in the community 
have the capacity of curing TB. For example, one TB 
patient said, ‘here is a medicine called Irubukoi and most 
of the people use them to cure TB and pneumonia’’ (TB 
Patient, 4 TZ]
Apart from the local medicine and traditional healers, 
some community members believe TB is caused by spirits 
and can be treated through prayers in churches or 
mosques as illustrated below:






TB patient care givers 27
Local government authorities 29
Medical administrators and District Tuberculosis 
and Leprosy Coordinators (DTLCs)
37
Medical practitioners/clinic staff/Directly 





Community members participating in FGDs and interviews 
constituted the largest proportion of participants.
FGDs, focus group discussions; TB, tuberculosis.
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‘…There is this community of Nubis, they are our 
relatives, and we intermarry a lot, but they love their 
things to do with spirits. They believe a sick person is 
possessed by spirit and hence they go to their spiritu-
al leaders for prayers, yet they have TB or HIV…’ [TB 
Care Giver, 3 KE]
The beliefs which make people think of other ailments 
first when they are confronted with TB symptoms and/
or make them delay seeking treatment from HCFs or not 
seek it at all are quite prevalent among communities in 
the region. One healthcare provider shared example of 
how such beliefs manifest: ‘we meet some clients who 
had non- medical treatment from home, because of the 
culture. There are people who tried to use herbs. They 
tried to treat a number of conditions with herbs. And they 
tend to take too long to seek treatment from HCFs. An 
attitude like: ‘this one is culturally known to do it, even 
if you go for the medical treatment, it may not help, let’s 
use this’ [Health care provider, 1 KE].
Another healthcare provider said ‘everyone knows 
about this, even children. Their mothers first buy them 
syrups over the counter not prescribed by the doctor and 
they try treatment at home. When their treatment fails or 
seems to be failing that is when they think of going to the 
clinic. When we ask what treatment they took from home, 
people often buy first- line antibiotic treatment- someone 
can buy amoxicillin, if there is no improvement, they 
change to another antibiotic of different name thinking 
that there will be improvement thereafter.’ [Health care 
provider, 2 TZ]
Knowledge of TB, diagnosis and treatment
Knowledge about TB disease, causes, recognition and 
interpretation of signs and symptoms, and treatment was 
found to be low in the community members with about 
50% of respondents having some basic knowledge of TB. 
The low knowledge of TB was more pronounced rural 
communities compared with their counterparts living in 
the urban areas. The statements below illustrate the low 
knowledge on TB disease.
‘…TB is transmitted by doing heavy jobs like farm-
ing and engaging in sexual intercourse with girls and 
smoking…’ [TB Patient, 1 TZ].
In contrast to the general community members, people 
who have suffered from TB and caregivers of TB patients 
had high awareness of TB and basic knowledge of TB 
disease. The majority of TB patients and their caregivers 
knew basic facts about TB transmission, common signs 
and symptoms, and that TB is curable. In addition, some 
even mentioned about the association between TB and 
HIV. For example, one interviewee said:
‘…TB is a chronic illness. TB symptoms are severe 
cough of more than two weeks, coughing the sputum 
which are blood mixed, fever during the night and 
overnight sweating.’’ [TB Survivor, 2 TZ].
Despite the high awareness of TB among TB patients 
and their caregivers, it was noted that most TB patients 
and caregivers were not aware of TB symptoms before they 
had suffered from the disease. It was only after diagnosis 
and getting education from the healthcare providers that 
they got to know some basics of TB as one TB survivor 
commented,
‘…I really never thought it could be TB because I was 
coughing, and I thought it was a normal cough or 
something like pneumonia. TB is not a small disease’ 
[TB Survivor, 3 TZ].
As a result of low awareness of TB disease, recognition 
and interpretation of TB symptoms and signs among 
community members, perceived symptom severity was 
what pushed them as last resort to take their patients to 
the health facility for diagnosis and treatment, as stated 
below:
‘…First the (Tb patient) started coughing and to lost 
weight, we saw his body changing daily, he lost ap-
petite, he was tired all the time, very much sweating 
especially at night he was complaining about chest 
pain. From there his condition continued to be 
worse, we decided to take him to hospital…’ [Male 
Care Giver, 1 KE].
Another caregiver alluded to this notion by stating
Figure 1 The map showing the surveyed regions and 
counties in three East African Community Countries.
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‘…my son experienced regular fever and coughing 
for almost four weeks then we brought him to the 
hospital. But we did not notice its TB’. We Tanzanians 
have a bad habit of taking things easy. We thought 
it was a normal cough but after four weeks…he was 
getting very serious, that is when we brought him to 
the hospital where we found it is TB’ [Female Care 
Giver, 2 TZ].
Size, taste and number of pills and side effects of TB treatment
Apart from complementary medicine, beliefs and tradi-
tions, the number and size of pills was among the chal-
lenges mentioned to interfere with treatment adherence 
as reported by a male caregiver ‘…the huge size of these 
pills sometimes discourages patients from swallowing 
them…when I used to give the pills to my father he used 
to complain that they were too big to swallow and thus he 
wanted the small ones.’[Male care giver, 4 TZ] Another 
interviewee mentioned ‘…the moment you are discov-
ered remember you go, you undergo these 4 tablets plus 
the other ones 5, plus if you are co- infected more, so 
its pill burden…’ [TB patient,5 UG]. In a focus group 
discussion, a female survivor of TB [4 TZ] pointed out 
bitterness of the pills as another hindrance to taking the 
medicines and suggested sugar- coating the pills to make 
them more palatable.
The side effects associated with anti- TB drugs were 
pointed out as one of the major reasons as to why TB 
patients apparently fail to complete treatment. Drawing 
on their lived experience, respondents shared descrip-
tions of the side effects of the drugs ‘…All of them 
(patients on treatment) will complain of dizziness. Others 
have vomiting if they are not getting used to the medi-
cine. Others reacted to the medicine and lost hearing. 
What we call neuropathy, the nerves, they will get a lot 
of pain- you get up in the morning and you are unable 
to walk. When you step on the ground you feel like you 
are stepping on thorns and sharp objects.’ [Health care 
provider, 3 TZ].
Another healthcare provider added by saying ‘…Some-
body treated, declared cured, comes back with a cough. 
About three of them, all of them I managed to send the 
samples to Mulago for what we call mycology culture. All 
of them have shown to be having fungal diseases, which is 
making them weak and when they are coughing this time 
they don’t cough like TB. The cough is severe. They get 
wasted in a shorter time. That fungus it is not TB. Well, 
the drug you use for treating TB are very difficult drug, 
in terms of their compromising the immunity. Now, once 
immunity drop to a certain point and remember the lung 
is damaged. And still this fungus also takes advantage of 
the weak immunity and the damaged lung to develop in 
your body.’ [Healthcare provider, 4 UG]
Stigma associated with TB disease
The study found that stigma was rife among the patients, 
family, relatives, friends and neighbours, including 
perceived and enacted stigma as well as discrimination. 
All TB patients interviewed reported experiencing stigma 
and discrimination from the immediate family members, 
the community and even at health facilities. The following 
statements illustrate how TB patients were stigmatised 
and discriminated
‘…I used to be fearful; ashamed I could not move a 
lot because I knew people were talking about me. I 
stayed in the house. I would just get outside next to 
my house and warm myself in the sun because I did 
not have visitors, they did not want to come…’ [TB 
patient, 7 KE].
In addition, TB patients are also stigmatised to having 
HIV too. There was a sense in the community that if one 
has TB, s/he is most likely to have HIV too. Talking about 
this misconception, one participant said ‘…most of the 
people know that when a person is having TB then this 
person is likely to have HIV/AIDS as well…[Commu-
nity member, 1 TZ]’’. Another one said ‘…because they 
appear emaciated, people might think they have HIV but 
some may not be having HIV they are just TB without 
other comorbidity…So I think people should not be 
afraid the tests… ’ [Private practitioner, 1 TZ]
Fear of HIV testing
The policy recommending HIV test for every TB patient 
together with the perception that TB patient must have 
HIV, has created fear among people fear to go for TB 
testing. The community members fear that they will be 
asked to check for HIV status as well which eventually 
delays access and use of the TB diagnostic services. The 
following statements illustrate the fear of HIV testing in 
the community.
‘…People fear to go to the hospital for TB diagnosis 
because they will be diagnosed and if they have TB, 
HIV will also be tested …’ [TB Survivor, 6 TZ]
Socioeconomic factors
Costs related to health facilities
A common view among most of respondents especially in 
the rural settings was that costs incurred in using health 
services including transportation was a significant socio-
economic barrier to accessing TB diagnosis and treat-
ment services. For example, one TB patient said ‘… when 
you plan to come to the hospital you need to arrange for 
bus fair, accommodation cost. You cannot come to town 
and go back home the same day… It is very far’ [Female 
TB Patient, 13 TZ]. This view was echoed by another 
informant who said ‘…I use  Tz. shs. 2,000/=to pay for the 
bus transport coming to hospital and returning home…’ 
[Female Care Giver, 5 TZ].
‘…Sputum analysis you pay  Ug. shs. 20,000/= for the 
gram stain that is when you are expecting a bacteri-
al infection: and the ZN (Ziehl- Neelsen) that is now 
testing for the AFBs (Acid- Fast Bacilli), which is for 
TB, which causes TB. So, the whole test cost  Ug. shs. 
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20, 000/=  Ug. shs. 10,000/= for the gram stain and  Ug. 
shs. 10, 000/= for the ZN.’ [TB patient, 9 UG]
Despite the costs, geographical accessibility also played 
a significant role in hindering community members to 
access to health facilities for TB diagnosis and treatment 
adherence. One caregiver commented ‘…so from here 
to our hospital is a bit far since we are in the interior and 
especially when we have rains like this time, to travel from 
here to the hospital is very difficult because accessibility 
of roads is very hard…’ [Care giver, 6 TZ].
It is the general view of respondents that their respec-
tive HCFs are ill- equipped for TB care, as indicated by 
shortage of drugs to treat TB, especially Multi- Drug Resis-
tant TB (MDR- TB) and they have to refer patients. A 
respondent, for example, testified:
‘… In case we don’t have medicine at that time for 
MDR- TB you would have to transport the patient to 
Mulago. The problem is appropriate vehicle to trans-
port them as they couldn’t travel in the public bus. 
We must get a pickup (truck) for them to sit and 
refer them. We usually refer to the national TB cen-
tre. But that is not encouraged, because you are now 
spreading a dangerous disease. It is easier to bring 
the medicine- source nearer than sending the person 
farther afield to collect the medicine.’ [Healthcare provid-
er, 5 UG].
Lack of food during treatment
Shortage of food was one the socio- economic concerns 
highlighted for non- adherence to TB medication. This 
theme recurred throughout the data set as a significant 
socioeconomic barrier to keeping up with medication 
adherence. Due to lack of food, some patients skipped 
medication or even stopped medication. For example, 
one TB patient said
‘…there are few times when I skipped my dose if I 
did not have enough food to eat, because if you take 
those drugs on an empty stomach, they make you feel 
very bad for like two three hours’. [TB Patient, 10 
KE] Another TB patient also echoed this view, ‘…TB 
medicine is a dose of six months, and you should take 
it every day. Others do stop using the medicines be-
cause of lack of food’’ [TB patient, 11 TZ].
Work patterns and responsibilities
Working patterns and conditions such as mining not 
only creates a high- risk environment for TB transmission 
but also prevented miners from accessing TB diagnosis 
as well as treatment adherence. For example, one miner 
commented ‘…The young men working in mining areas 
because we are at a very high risk of contracting TB but 
when we fall sick, our bosses do not give us anything…’ 
[Community member, 2 TZ]. Apart from working 
patterns and conditions, family responsibilities among 
caregivers somehow do play role in hindering caregivers’ 
accessing TB diagnosis services and even keeping up with 
TB treatment adherence. This notion was shared by one 
village leader who stated ‘…most of the TB patients are 
poor, so when they feel relief even in the middle of the 
dose, they tend to stop and get back to work in order to 
earn a living…’ [Village leader, 3 TZ].
Lifestyle
The nomadic lifestyle among the Maasai tribe also poses 
as a socioeconomic barrier to seeking TB diagnosis and 
treatments services at health facilities. Moving from 
one place to another greatly interferes with medication 
adherence. ‘…Maasai are living very far from the health 
centres because they tend to move from place to place far 
from town looking for the pasture for their animals…’ 
[TB Care Giver,8 TZ]. Alcohol consumption among the 
young men in the societies have also shown to be a contrib-
uting factor to non- adherence with TB medications. For 
example, one miner commented ‘…most of the young 
men in this street are alcohol drinkers and this tendency 
disturbs the adherence to TB medicines…’’ [Community 
member, Miner, 3 TZ].
DISCUSSION
The study aimed to assess and elucidate how the socio-
economic and cultural factors affect the uptake and util-
isation of diagnostic and treatment tools for TB in East 
Africa. The study has brought to the fore the views of a 
diverse of group of stakeholders and unravels the simi-
larities in socioeconomic- cultural perspectives across 
national borders. Most importantly, the study findings 
reveal the criticality of understanding the sociocultural 
context of service users in order for health systems to 
offer effective healthcare. including patients, survivors, 
caregivers, healthcare workers and administrators, and 
policymakers. Socioeconomic and cultural issues high-
lighted by the study: knowledge of disease signs and 
causes, perverted beliefs and use of complementary medi-
cine, stigma and deterrent costs of care are fundamental 
and can be generalised to other disease conditions. For 
instance, anecdotal information shows COVID-19 has 
caused rise in stigmatisation of cough and use of alterna-
tive medicines. The recently reported decline in TB noti-
fication could be reflecting people fearing to seek formal 
treatment for cough and resorting to purchasing medi-
cines over- the- counter or using traditional herbs29
Lack of knowledge or correct information about TB 
transmission and treatment was among the prominent 
factors hindering timely and successful diagnosis and 
treatment of TB. These findings concur with what other 
studies have found on this topic.14 19–22 30 31 Shortage of 
communication channels like radios, televisions (TVs), 
and internet exacerbate lack of awareness of TB and 
existing medical remedies among people mostly in rural 
areas and mining industry. Poor or no electricity supply 
complicate the use of TVs and computers. Misinforma-
tion which is currently rampant in the COVID-19 era has 
always been a hinderance to uptake medical interventions 
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and can only be counteracted by proactive sharing of 
facts.
Access and use of health technologies is further compro-
mised by poor transport infrastructure, high illiteracy rate 
and lack of well- equipped HCFs and specialised health-
care providers.32 33 Analysis of the health system barriers 
(first part of this study) points to the centralised imple-
mentation model as the most cost- effective of ensuring 
maximal uptake and utilisation of high- tech diagnostic 
technologies. However, this can only be effective if the 
governments invested in good transport infrastructure 
connecting rural and urban areas to ensure timely sample 
referral and delivery of diagnostic samples. Investing in 
information communication technologies would not only 
ensure higher awareness of TB and its care services but 
also communicating laboratory results to patients once 
tests are completed. Hiring and retaining well trained 
healthcare practitioners and giving them refresher 
training on novel health technologies cannot be more 
emphasised.
The current TB treatment regimen is a combination 
of four antibiotics for 6 months in drug sensitive TB and 
more months for drug resistant TB.34 Presence of comor-
bidity like HIV worsens the pill burden. The pill burden 
(size and number of pills) was highlighted by participants 
as major hinderance to adherence to treatment. Side 
effects such as vomiting, and loss of hearing aggravated the 
problem. This calls for medicines developers to find inno-
vative ways of combining drugs into single pills and less 
bitter to increase palatability. Finding fewer toxic drugs 
or combinations of drugs should be the main agenda 
of drug manufacturers and clinical trials. Increasing 
patient–practitioner communication and interaction has 
been suggested as one of the ways to manage and mitigate 
side effects caused by medicines and ensuring treatment 
adherences.35 Patients should be well informed about the 
side effects, pill burden as well as supportive nutritional 
foods they need while on treatment.
Our study found stigma to TB infection was mostly 
associated with HIV infection, since the general commu-
nity perception is that anyone testing positive for TB is 
also HIV infected. As much as the perception is incor-
rect because HIV- TB coinfection is estimated at 40% 
in East Africa, it shapes the attitudes in the negative 
direction.36 This contrasts the TB stigma in West Africa 
where TB is associated with ethnic or family curse, being 
grossly unhygienic and very contagious so much that even 
healthcare practitioners shun working with TB patients.37 
Consequently, stigma make people more inclined to 
keeping their ailment a secret and reduces willingness 
to seek medical care. This in turn stops or delays access 
to appropriate diagnostic and treatment services.17 18 38 39 
We believe poor understanding of the causes and signs 
of disease like TB creates a knowledge gap that people 
tend to fill with superstition and stigma. Those purposed 
to have knowledge such as healthcare practitioners, their 
stigma may be driven by lack of personal protective equip-
ment (PPE) for which they ensure safety by avoiding 
patients with contagious diseases like TB. Sensitisation 
of both community and healthcare practitioners coupled 
with provision of appropriate PPE would go a long way in 
resolving the stigma issue.
Beliefs and myths about the causes and transmission 
for TB including being related to witchcraft, family curse 
and having a long Uvula (known as Kilimi in Swahili both 
in TZ and KE) as cause of recurrent coughing raised 
stigma and discrimination of TB patients. As a result, the 
patient pathway to care is complicated as most patients 
resort to seeking remedy from traditional healers, pala-
tine uvula cutters before going to the formal healthcare 
centres. These kinds of behaviours and beliefs have been 
reported in other studies in done in Tanzania38 and in 
other African countries.40 Action follows belief and so 
someone who believes witchcraft is the cause of TB will by 
default consult a traditional healer or someone with spiri-
tual powers first, which prolongs the pathway to diagnosis 
and treatment at formal HCFs.35 38
Our study is the first large qualitative study combining 
information from three Eastern Africa countries. It has 
highlighted the critical impact socioeconomic and cultural 
barriers have on uptake and utilisation of diagnostic and 
treatment technologies. Drawing from the findings it appears 
the largest ‘roadblock’ to uptake and utilisation of diagnostic 
and treatment tools occurs at the primary point of access in 
the patient pathway. This is the point between feeling poorly 
and getting diagnosis. It therefore makes more sense for 
most investment to be made at this primary point of access 
in order to shorten the path to access of healthcare services, 
which in turn would increase uptake, and utilisation of health 
technologies (figure 2).
Strengths and limitations
This study brought together diverse group of stakeholders 
ranging from community members at village level to 
Figure 2 Diagrammatic representation of the impediments 
of access, uptake and utilisation of diagnostic and treatment 
tools in the patient pathway. Most hinderance is experienced 
at the primary level where the patient first seeks healthcare 
intervention during their ailment. The path is not straight 
reflecting the different barriers and routes the patient goes 
through to get or adhere to care.
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practitioners and policy makers at regional and national 
level. Their views give an enriched perspective of how socio-
economic and cultural barriers affect uptake and utilisation 
of health technologies within the health system. Triangula-
tion of data sources strengthens the validity of our results. 
The findings represent voices of real people and can be 
generalised to other diseases in as far as healthcare access is 
concerned. We note that views of 712 participants may not be 
representative of everyone in the study countries. Reliance 
of participant’s ability to recall events of their previous inter-
actions with the healthcare system raises risk of inaccuracy 
in the data collected. Quite importantly, however, is that our 
interviewers were well trained with experience in conducting 
social science studies.
CONCLUSION AND RECOMMENDATIONS
Our study has shown that socioeconomic and cultural 
factors are important barriers to uptake and utilisation 
of diagnostic and treatment tools. While our study was 
done in the context of TB, we believe these challenges 
are fundamental and can apply to any other disease. 
Resolving awareness/knowledge gaps, beliefs, stigma and 
improving socioeconomic welfare of affected communi-
ties is an antidote that cuts across many disease conditions. 
We recommend future socioeconomic- cultural interven-
tional studies with monitoring and evaluation compo-
nent to assess and quantify impact of the interventions. 
Learning from end users by diagnostics and medicines 
developers will enable them to develop effective diag-
nostic and treatment tools. Social protection programmes 
to people working in high- risk industries like mining and 
interventions to reduce use of dirty sources of energy like 
firewood, charcoal, coal etc are critical for reducing the 
burden of respiratory diseases like TB. Focusing invest-
ment at the primary point of healthcare access is critical 
to maximising uptake and utilisation of diagnostic and 
treatment tools.
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